Efficacy of Antiseizure Medications in Wolf–Hirschhorn Syndrome

Abstract

Wolf–Hirschhorn syndrome (WHS) is caused by deletion of the terminal region of chromosome 4 short arm and is frequently associated with intractable epilepsy. This article evaluates the clinical features of epileptic seizures in WHS and the therapeutic efficacy of oral antiseizure medications (ASMs). Patients with WHS who were treated for epilepsy at the Saitama Children's Medical Center under 5 years of age were included. WHS was diagnosed based on genetic tests and clinical symptoms. Medical records regarding the age of onset of epilepsy, seizure type, treatment of status epilepticus (SE), and effectiveness of ASMs were retrospectively reviewed. Oral ASMs were considered effective when seizures were reduced by at least 50% compared with the premedication level. Eleven patients were included in the study. The median age at the onset of epilepsy was 9 months (range: 5–32 months). Unknown-onset bilateral tonic-clonic seizure was the most common type of seizure, occurring in 10 patients. Focal clonic seizures occurred in four patients. Ten patients exhibited recurrent episodes of SE, and its frequency during infancy was monthly in eight patients and yearly in two. SE occurrence peaked at 1 year of age and decreased after 3 years of age. The most effective ASM was levetiracetam. Although WHS-associated epilepsy is intractable with frequent SE occurrence during infancy, improvement in seizure control is expected with age. Levetiracetam may be a novel ASM for WHS.

Keywords

chromosomal abnormality - status epilepticus - thermal hypersensitivity - novel antiseizure medications

Publikationsverlauf

Eingereicht: 05. August 2022

Angenommen: 12. April 2023

Accepted Manuscript online:
19. April 2023

Artikel online veröffentlicht:
31. Mai 2023

• References

• 1 Paprocka J, Kaminiów K, Yetkin O. et al. Clinical and epilepsy characteristics in Wolf-Hirschhorn syndrome (4p-): a review. Seizure 2022; 22: 1059-1311
• 2 Battaglia A, Filippi T, South ST, Carey JC. Spectrum of epilepsy and electroencephalogram patterns in Wolf-Hirschhorn syndrome: experience with 87 patients. Dev Med Child Neurol 2009; 51 (05) 373-380
• 3 Ho KS, Markham LM, Twede H. et al. A survey of antiepileptic drug responses identifies drugs with potential efficacy for seizure control in Wolf-Hirschhorn syndrome. Epilepsy Behav 2018; 81: 55-61
• 4 Kagitani-Shimono K, Imai K, Otani K. et al. Epilepsy in Wolf-Hirschhorn syndrome (4p-). Epilepsia 2005; 46 (01) 150-155
• 5 Shimizu K, Wakui K, Kosho T. et al. Microarray and FISH-based genotype-phenotype analysis of 22 Japanese patients with Wolf-Hirschhorn syndrome. Am J Med Genet A 2014; 164A [phone]
• 6 Karalok ZS, Arhan EP, Erdogan KM, Gurkas E. Excellent response to levetiracetam in epilepsy with Wolf-Hirschhorn syndrome. Childs Nerv Syst 2016; 32 (01) 9-11
• 7 Battaglia D, Zampino G, Zollino M. et al. Electroclinical patterns and evolution of epilepsy in the 4p- syndrome. Epilepsia 2003; 44 (09) 1183-1190
• 8 Ho KS, South ST, Lortz A. et al. Chromosomal microarray testing identifies a 4p terminal region associated with seizures in Wolf-Hirschhorn syndrome. J Med Genet 2016; 53 (04) 256-263
• 9 Nevado J, Ho KS, Zollino M. et al; Wolf-Hirschhorn Spain's Working Group. International meeting on Wolf-Hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. Am J Med Genet A 2020; 182 (01) 257-267
• 10 Nakano Y, Fujita M, Ogino K. et al. Biogenesis of GPI-anchored proteins is essential for surface expression of sodium channels in zebrafish Rohon-Beard neurons to respond to mechanosensory stimulation. Development 2010; 137 (10) 1689-1698